Clinically localised prostate cancer

British Medical Journal

Volumn 333, Issue 7578, 2006, Pages 1102-1106

  Wilt, Timothy J ^a   Thompson, Ian M ^b  

^a Minneapolis VA Center for Chronic Disease Outcomes Research   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

BREAST TENDERNESS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL TRIAL; DEPRESSION; DIGITAL RECTAL EXAMINATION; DRUG COST; ERECTILE DYSFUNCTION; FATIGUE; FRACTURE; HEMATURIA; HOT FLUSH; HUMAN; LIBIDO DISORDER; MEMORY DISORDER; MOOD CHANGE; MORBIDITY; MUSCLE ATROPHY; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; URINARY TRACT OBSTRUCTION;

ANDROGEN ANTAGONISTS; BIOPSY; BRACHYTHERAPY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF HEALTH CARE; RISK ASSESSMENT; RISK FACTORS;

EID: 33845234584     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39022.423588.DE     Document Type: Review

References (26)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
2. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol 2006;28:737-45.
3. Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 2005;97:1768-77.
4. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
5. Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptomas at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000;85:1037-48.
6. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Int Med 2002;137:917-29.
7. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level of ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
8. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Feng Z, et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34.
9. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United Sates: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97:1132-7.
10. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer. Cochrane Database Syst Rev 2006;3:CD004720.
11. Barry MJ. The PSA conundrum. Arch Intern Med 2006;166:7-8.
12. McNaughton-Collins M, Fowler FJ Jr, Caubet JF, Bates DW, Lee JM, Hauser A, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med 2004;117:719-25.
13. Ransohoff D. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 2002;113:663-7.
14. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
15. Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DC, Stroud L, et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 2006;106:1865-74.
16. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
17. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
18. Paulson, DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502-4.
19. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9.
20. National Institute for Health and Clinical Excellence. Low dose rate brachytherapy for localised prostate cancer. www.nice.org.uk/IPG132
21. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
22. Shahinian VB, Fuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006;166:465-71.
23. Wilt TJ, Partin MR. Reducing PSAnxiety: The importance of noninvasive chronic disease management in prostate cancer detection and treatment. Am J Med 2004;117:796-8.
24. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000;283:3217-22.
25. Partin MR, Wilt TJ. Informing patients about prostate cancer screening: identifying and meeting the challenges while the evidence remains uncertain. Am J Med 2002;113:691-3.
26. Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS. Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol 2003;21:1928-36.